![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Gives Thumbs Up to Gilead’s Odefsey
FDA Gives Thumbs Up to Gilead’s Odefsey
![](https://www.fdanews.com/ext/resources/test/Device_Images4/FDA_Logo_Large.gif?t=1486528488&width=430)
March 7, 2016
The FDA has approved Gilead’s second TAF-based single-tablet regimen Odefsey for the treatment of HIV infection.
Odefsey is a single-tablet combination of emtricitabine, rilpivirine and tenofovir alafenamide — or TAF — and is designed to treat HIV-1 in patients 12 years of age or older with no history of antiretroviral treatment.
The approval is part of a development and commercialization agreement between Gilead and Janssen established in 2009. Gilead contributed emtricitabine and tenofovir alafenamide, and Janssen contributed rilpivirine.
Upcoming Events
-
21Oct